PARP1 and prostate carcinoma: The same mechanism is responsible for an increased activity of PARP inhibitors also in endometrial or prostate cancer cells with loss of PTEN function compared to wild-type cells, suggesting a potential role of PTEN as a marker of primary resistance to PARP inhibitors [79, 80].